Share
Journal Information
Issue
Vol. 27. Issue. S5.October 2007
Pages 1-67
A collection of structuralized and critical summaries of the nephrology literature
C. Quereda, F. García López, V. Barrio
Nefrologia (English Version). 2007;27 Supl 5:1-3
Is tacrolimus effective as monotherapy in primary membranous glomerulonephritis?
M. Cobo, D. Hernández
Nefrologia (English Version). 2007;27 Supl 5:4-5
What are the effectiveness and safety of low-dose Cyclosporin as monotherapy or combined with corticosteroids used as induction and long-term therapy in idiopathic membranous nephropathy with nephrotic syndrome?
X. Fulladosa
Nefrologia (English Version). 2007;27 Supl 5:6-7
Is Azathioprine maintenance therapy equivalent to Cyclosporin A therapy to prevent recurrences of proliferative forms of lupus nephritis?
A. Segarra, C. Quereda
Nefrologia (English Version). 2007;27 Supl 5:8-9
Can Azathioprine and corticosteroids maintenance therapy replace Cyclophosphamide and corticosteroids in proliferative lupus nephritis in terms of efficacy and safety?
C. Quereda , F. García López
Nefrologia (English Version). 2007;27 Supl 5:10-1
Does the implementation of an educational and health care professionals alert system including patient education on essential AHT improve the management of this disease?
A. M. Tato, F. García López
Nefrologia (English Version). 2007;27 Supl 5:12-3
Is it better to use an ACE inhibitor (lysinopril) rather than a calcium-channel blocker (amlodipine) for managing hypertension patients with high cardiovascular risk?
R. Marín Iranzo
Nefrologia (English Version). 2007;27 Supl 5:14-5
Can blood pressure control independently reduce the risk for developing microalbuminuria in type 2 Diabetes patients without diabetic nephropathy?
A. Martínez-Castelao, J. L. Górriz, C. Quereda
Nefrologia (English Version). 2007;27 Supl 5:16-7
Does the target of an Hb value of 13.5 g/dL versus 11.3 g/dL in EPO-managed stages 3 and 4 chronic renal disease decrease cardiovascular events and mortality?
R. Saracho
Nefrologia (English Version). 2007;27 Supl 5:18-9
Is it better to normalize hemoglobin rather than partially correcting anemia in stages 3-4 chronic renal disease patients to decrease cardiovascular events?
R. Saracho Rotaeche
Nefrologia (English Version). 2007;27 Supl 5:20-1
How do the different hemoglobin therapeutic targets affect the mortality and cardiovascular events when managing anemia with different erythropoiesis-stimulating agents in chronic renal failure?
F. García López
Nefrologia (English Version). 2007;27 Supl 5:22-3
Does therapy with spironolactone increase the effect of ACEIs and ARA-II for managing proteinuria and renal failure progression in patients with chronic renal disease?
A. Ramos, C. Caramelo
Nefrologia (English Version). 2007;27 Supl 5:24-5
What are the benefits and risks of calcimimetic agents in the management of secondary hyperparathyroidism in chronic renal failure?
F. Rivera
Nefrologia (English Version). 2007;27 Supl 5:26-7
What is the role of progenitor endothelial cells in chronic renal disease?
A. Ramos, C. Caramelo
Nefrologia (English Version). 2007;27 Supl 5:28-9
Is tolvaptan (a vasopressin V2 receptor antagonist) effective in the management of isovolumic and hypervolaemic hypernatremia?
F. Ortiz
Nefrologia (English Version). 2007;27 Supl 5:30-1
Is the incidence of acute renal failure (ARF) lower by using selective nonsteroidal anti-inflammatory drugs (NSAIDs)?
V. Barrio Lucía, F. García López
Nefrologia (English Version). 2007;27 Supl 5:32-3
Besides N-acetylcysteine, which among other regimens better prevents iodinated radiocontrast media-associated nephropathy: hydration with normal saline, with sodium bicarbonate, or both with ascorbic acid (vitamin C)?
V. Barrio, M. Velo
Nefrologia (English Version). 2007;27 Supl 5:34-5
Does furosemide administration improve the prognosis or the need for replacement therapy in acute renal failure?
V. Barrio, C. Quereda
Nefrologia (English Version). 2007;27 Supl 5:36-7
Does adding dialysis doses to continuous hemofiltration improve the prognosis in acute renal failure (ARF)?
V. Barrio, F. Liaño
Nefrologia (English Version). 2007;27 Supl 5:38-9
Do vesicoureteral reflux and/or antibiotic prophylaxis have an influence on the recurrence of pyelonephritis, urinary infections, and occurrence of renal scars after the first episode of acute pyelonephritis?
M. Espino Hernández
Nefrologia (English Version). 2007;27 Supl 5:40-1
Can intensification of the nocturnal session of automated peritoneal dialysis be compared with, or even improve, the outcomes from prescription based on diurnal supplementary changes, while improving the patients'' quality of life?
M. Pérez Fontán, A. Rodríguez Carmona
Nefrologia (English Version). 2007;27 Supl 5:42-3
Is high peritoneal transport an independent risk factor for mortality and/or survival in peritoneal dialysis patients?
M. J. Fernández-Reyes, M. A. Bajo
Nefrologia (English Version). 2007;27 Supl 5:44-5
Does the pigtail catheter offer better outcomes than straight swan-neck Tenckhoff catheter?
G. del Peso, M. A. Bajo
Nefrologia (English Version). 2007;27 Supl 5:46-7
As compared with standard solutions, do low-content glucose degradation products (GDPs) peritoneal dialysis solutions improve the patient''s survival?
C. Remón, P. L. Quirós
Nefrologia (English Version). 2007;27 Supl 5:48-9
Are ANDY-Disc® and Ultrabag® connection systems comparable in terms of peritonitis rate and technique survival in peritoneal dialysis patients?
P. L. Quirós, C. Remón
Nefrologia (English Version). 2007;27 Supl 5:50-1
EIs the follow-up of quality indicators and combined achievement of several goals associated with better clinical outcomes in hemodialysis patients?
F. Álvarez-Ude, M. D. Arenas
Nefrologia (English Version). 2007;27 Supl 5:52-3
Does immunosuppressive induction with anti-thymocyte globulin offer any advantage over anti-IL-2R monoclonal antibodies in patients with deaddonor renal transplant and high risk for delayed graft function or acute rejection?
J. J. Amenábar Iríbar, F. J. García López
Nefrologia (English Version). 2007;27 Supl 5:54-5
Does the use of ACEI/ARA-II have any influence on patients and graft survival after renal transplantation?
D. Hernández, M. Cobo
Nefrologia (English Version). 2007;27 Supl 5:56-7
Does a therapeutic regimen without anti-calcineurin agents entail a low risk for acute rejection in pediatric renal transplant?
J. M. Díaz
Nefrologia (English Version). 2007;27 Supl 5:58-9
Hemoglobin target levels in chronic renal failure: evidence and clinical practice guidelines
F. García López, R. Saracho
Nefrologia (English Version). 2007;27 Supl 5:60-4
Instructions for doing a structuralized summary and critical analysis of an observational study
D. Hernández
Nefrologia (English Version). 2007;27 Supl 5:65-7
Special content about COVID-19
- Strategies for prevention and treatment of SARS-COV-2 infection in patients with chronic kidney disease: Literature review
- Dysregulation of ferroptosis may participate in the mitigating effect of CoCl 2 on contrast-induced nephropathy
- Acute interstitial nephritis following COVID-19 vaccination
- De novo IgA nephropathy in a kidney transplant recipient after SARS-CoV-2 vaccination
Open access
This work is licensed under a Creative Commons Attribution 4.0 International License.
Publish in
Nefrología
NEFROLOGÍA
AL DÍA
AL DÍA
